$ query --compound PT-141 --field overview
PT-141 is approved for one narrow use and unapproved for everything the search traffic wants — here is the record, read straight off the label and the trials.
A status-and-access digest of bremelanotide: what the FDA approved, what the studies measured, and where the approval boundary actually runs. Every claim sourced.
The short version
PT-141 (also called bremelanotide) is a small lab-made peptide — a short chain of amino acids — that acts inside the brain rather than on blood flow. In June 2019 the US Food and Drug Administration approved it under the generic name bremelanotide for one specific use: hypoactive sexual desire disorder, or HSDD (persistently low sexual desire that causes real distress), in premenopausal women [7]. That is the only approved use. Everything the search traffic tends to ask about — PT-141 for men, for erectile dysfunction, for postmenopausal women, or for "performance" — is off-label or unapproved, meaning the FDA has not cleared it for that purpose even though some early studies exist [1]. On top of that, material sold loosely as "PT-141 research chemical" sits entirely outside the approval framework, with no regulator checking what is in the vial. This site reads the published evidence and the approved label, flags where each claim stands, and never recommends a dose. The full picture of PT-141 benefits and PT-141 effects — including the downsides — is documented page by page.
What is PT-141
PT-141 is a synthetic cyclic heptapeptide — a ring of seven amino acids — modeled on alpha-MSH (alpha-melanocyte-stimulating hormone), a natural signaling molecule the body makes from a precursor protein called POMC. It is a melanocortin receptor agonist: it switches on melanocortin receptors, chiefly MC4R and MC3R, that sit mostly in the brain [1]. That central location matters. Unlike PDE-5 inhibitors (the familiar erectile-dysfunction drugs that work on blood vessels), PT-141 acts on the neural circuitry of sexual motivation in the hypothalamus and limbic system, not on vascular smooth muscle [1]. In animal work, systemic PT-141 produced erections in rats and nonhuman primates and lit up hypothalamic neurons (measured as increased c-Fos), and it produced rapid, dose-dependent erectile activity in men with erectile dysfunction in early trials [1]. The international nonproprietary name for the molecule is bremelanotide; PT-141 and bremelanotide are two names for the same compound.
PT-141 peptide
As a peptide, the PT-141 peptide is built for stability: its cyclic lactam structure (a ring closed by a chemical bridge between two side chains) resists breakdown better than a straight, linear peptide would. It carries CAS number 189691-06-3, molecular formula C50H68N14O10, and a molecular weight near 1,025 daltons. The approved injectable form is given under the skin (subcutaneously); early development tried an intranasal spray, which was dropped because the absorbed amount varied too much between doses. PT-141 began its public life in the early 2000s as a candidate for both erectile dysfunction and female sexual dysfunction, with a completed Phase IIb erectile-dysfunction trial and Phase III plans, before the program refocused on the subcutaneous female-HSDD indication that ultimately reached approval [8]. The same molecule sold as a "research chemical" is not the approved pharmaceutical: it is unregulated material whose identity, purity, and concentration no agency verifies.
Where the evidence is strong, and where it isn't
The human evidence for the approved use is substantial. Two identical Phase 3 randomized controlled trials — together called RECONNECT, enrolling 1,267 premenopausal women with HSDD — found that bremelanotide 1.75 mg, injected under the skin as needed, produced a statistically significant improvement in sexual desire and reduced the distress tied to low desire over 24 weeks compared with placebo [3]. A 52-week open-label extension in 684 women found the desire improvements held up with no new safety surprises [4]. A mechanistic brain-imaging study added that melanocortin agonism increased desire for up to 24 hours and changed how the brain processed sexual cues [5]. Where the evidence thins out is everything outside that approved lane: the male erectile-dysfunction data are older and early-stage, and the effect sizes in the female trials, while statistically real, have been argued by critics to be modest in everyday terms. The honest summary is that PT-141 is well-studied for one indication and only lightly studied — or not formally studied — for the rest.